Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares were up 0.2% at $24.68 as of 12:18 p.m. ET on Tuesday, after a Form 144 filing showed company officer Robert Michael Carruthers sold 116,665 shares worth about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92. SEC

NASDAQ:EWTX · Stock Market
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Against that backdrop, Edgewise Therapeutics, Inc. is pulling back after a sharp midweek move tied to a clinical update in hypertrophic cardiomyopathy. As of the latest trade captured around 12:55 p.m. ET, EWTX traded near $26.00, down about 4.7% on the day, with an intraday range of $25.40 to $27.92 and volume above 1.0 million shares.
26 December 2025
·
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy. By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares.
24 December 2025
··
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

December 22, 2025 — Edgewise Therapeutics, Inc. is back in the spotlight as its stock price whipsaws following a sharp late-week surge and a fresh round of market commentary that mixes optimism about the company’s muscle-disease pipeline with familiar concerns about cash burn in a pre-revenue biotech.
22 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics, Inc. is ending mid-December 2025 in classic clinical-stage biotech fashion: big percentage swings, a sharp momentum breakout, and investors trying to decide whether the move is “new information” or simply “new positioning.” As of Saturday, December 20, 2025, EWTX is being widely quoted around $25.55—a level reached after a powerful jump in the prior U.S. session. StockAnalysis+1
20 December 2025
·
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

December 19, 2025 — Edgewise Therapeutics, Inc. is back in the spotlight after a sharp one-day rebound that followed a volatile stretch for the clinical-stage biotech. EWTX closed Dec. 19, 2025 at $23.01, up +8.79% on the day after trading between roughly $21.49 and $23.84 on elevated activity. Investing.com
19 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis
18 December 2025
··
Follow on Google News
Add as preferred source Open in Google News